Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | RIBECCA: ribociclib, a CDK4/6 inhibitor in ER+ breast cancer

Wolfgang Janni • 14 Dec 2020
SABCS 2020
Breast Cancer Letrozole Ribociclib
RIBECCA

Wolfgang Janni, MD, PhD, Ulm University, Ulm, Germany, discusses the RIBECCA trial, a Phase III study evaluating ribociclib, a CDK4/6 inhibitor, in combination with letrozole in women with estrogen receptor-positive (ER+), locally advanced or metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Wolfgang Janni

1:46
SUCCESS-A trial: ctDNA screening's potential in early-stage breast cancer recurrence prediction
Wolfgang Janni • 5 Dec 2023
1:37
SURVIVE study: liquid biopsy guided follow-up surveillance in early breast cancer
Wolfgang Janni • 5 Dec 2023
1:36
ctDNA assay for detection of recurrent disease in patients with early-stage breast cancer
Wolfgang Janni • 22 Sep 2021
1:19
MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole
Wolfgang Janni • 22 Sep 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals